NO309089B1 - FremgangsmÕte for fremstilling av taxanderivater - Google Patents

FremgangsmÕte for fremstilling av taxanderivater Download PDF

Info

Publication number
NO309089B1
NO309089B1 NO951201A NO951201A NO309089B1 NO 309089 B1 NO309089 B1 NO 309089B1 NO 951201 A NO951201 A NO 951201A NO 951201 A NO951201 A NO 951201A NO 309089 B1 NO309089 B1 NO 309089B1
Authority
NO
Norway
Prior art keywords
general formula
aliphatic
acid
compound
optionally
Prior art date
Application number
NO951201A
Other languages
English (en)
Norwegian (no)
Other versions
NO951201L (no
NO951201D0 (no
Inventor
Jean-Manuel Mas
Viviane Massonneau
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO951201L publication Critical patent/NO951201L/no
Publication of NO951201D0 publication Critical patent/NO951201D0/no
Publication of NO309089B1 publication Critical patent/NO309089B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO951201A 1992-10-05 1995-03-29 FremgangsmÕte for fremstilling av taxanderivater NO309089B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9211741A FR2696458B1 (fr) 1992-10-05 1992-10-05 Procédé de préparation de dérivés du taxane.
PCT/FR1993/000967 WO1994007877A1 (fr) 1992-10-05 1993-10-04 Procede de preparation de derives du taxane

Publications (3)

Publication Number Publication Date
NO951201L NO951201L (no) 1995-03-29
NO951201D0 NO951201D0 (no) 1995-03-29
NO309089B1 true NO309089B1 (no) 2000-12-11

Family

ID=9434119

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951201A NO309089B1 (no) 1992-10-05 1995-03-29 FremgangsmÕte for fremstilling av taxanderivater

Country Status (24)

Country Link
US (3) US5616739A (de)
EP (1) EP0663906B1 (de)
JP (1) JP3014760B2 (de)
KR (1) KR100311198B1 (de)
AT (1) ATE146174T1 (de)
AU (1) AU689080B2 (de)
CA (1) CA2146250C (de)
CZ (1) CZ283261B6 (de)
DE (1) DE69306591T2 (de)
DK (1) DK0663906T3 (de)
ES (1) ES2095081T3 (de)
FI (1) FI109793B (de)
FR (1) FR2696458B1 (de)
GR (1) GR3021997T3 (de)
HU (1) HU226412B1 (de)
MX (1) MX9305766A (de)
NO (1) NO309089B1 (de)
NZ (1) NZ256445A (de)
PL (1) PL182284B1 (de)
RU (1) RU2116303C1 (de)
SK (1) SK280627B6 (de)
TW (1) TW419472B (de)
WO (1) WO1994007877A1 (de)
ZA (1) ZA937318B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2696464B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2697522B1 (fr) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2698361B1 (fr) * 1992-11-20 1995-01-13 Rhone Poulenc Rorer Sa Procédé de préparation d'un acide oxazolidine-1,3 carboxylique-5.
IL107950A (en) 1992-12-15 2001-04-30 Upjohn Co b 7, b 8 - Matano - Taxols, their preparation and pharmaceutical preparations against malignant tumors containing them
US5973160A (en) * 1992-12-23 1999-10-26 Poss; Michael A. Methods for the preparation of novel sidechain-bearing taxanes
JPH09511212A (ja) * 1993-06-11 1997-11-11 ジ・アップジョン・カンパニー Δ▲上6▼,▲上7▼−タキソール類の抗悪性腫瘍的使用およびそれらを含む医薬組成物
FR2706457B1 (fr) * 1993-06-16 1995-07-28 Rhone Poulenc Rorer Sa Procédé de préparation d'un acide oxazolidinecarboxylique utile pour préparer des taxoïdes thérapeutiquement actifs.
US6005120A (en) 1993-07-20 1999-12-21 Florida State University Tricyclic and tetracyclic taxanes
JPH09505050A (ja) * 1993-11-12 1997-05-20 ジ・アップジョン・カンパニー ピリミジン−チオアルキルおよびアルキルエーテル化合物
IL127599A (en) * 1994-01-28 2004-06-01 Upjohn Co Process for preparing isotaxol analogs
US5679807A (en) * 1995-01-30 1997-10-21 Hauser, Inc. Preparation of taxol and docetaxel through primary amines
CA2170661A1 (en) * 1995-03-22 1996-09-23 John K. Thottathil Novel methods for the preparation of taxanes using oaxzolidine intermediates
GB9512471D0 (en) * 1995-06-20 1995-08-23 Pharmacia Spa Method for the preparation of taxol and its derivatives
US5688977A (en) * 1996-02-29 1997-11-18 Napro Biotherapeutics, Inc. Method for docetaxel synthesis
NZ332475A (en) * 1996-05-08 2000-05-26 Upjohn Co silylated baccatin derivatives, 3-(substituted amino)-3-phenyl-(2R,3S)-isoserinate derivatives, the oxazolidine ester thereof and other immediates used to prepare baccatin derivatives
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
CN1150149C (zh) 1997-08-21 2004-05-19 佛罗里达州立大学 紫杉烷类化合物的合成方法
AU1712899A (en) * 1997-12-23 1999-07-12 Bristol-Myers Squibb Company 7-deoxy-6-nitrogen substituted paclitaxels
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU2001288805A1 (en) 2000-09-22 2002-04-02 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
US6891050B2 (en) * 2001-08-10 2005-05-10 Dabur India Limited Process for the preparation of taxanes such as paclitaxel, docetaxel and structurally similar analogs
US6881852B2 (en) * 2002-02-05 2005-04-19 Dabur India Limited Process of purification of paclitaxel and docetaxel
US7247738B2 (en) * 2002-05-07 2007-07-24 Dabur India Limited Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids
US6900342B2 (en) * 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
ES2331791T5 (es) * 2002-06-26 2016-01-21 Medigene Ag Método de producción de una preparación catiónica de liposomas que comprende un compuesto lipófilo
AU2003273671A1 (en) * 2002-10-09 2004-05-04 Phytogen Life Sciences, Inc. Novel taxanes and methods related to use and preparation thereof
US6838569B2 (en) 2002-12-16 2005-01-04 Dabur India Limited Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
EP1633317A4 (de) 2003-05-16 2008-08-20 Intermune Inc Synthetische chemokin-rezeptor-liganden und anwendungsverfahren dafür
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7202370B2 (en) * 2003-10-27 2007-04-10 Conor Medsystems, Inc. Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク. 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1712552A1 (de) * 2005-04-11 2006-10-18 INDENA S.p.A. Teilsynthese für die Herstellung von 10-deacetyl-n-debenzoyl-paclitaxel
EP1647552A1 (de) * 2004-10-08 2006-04-19 INDENA S.p.A. Teilsynthese für die Herstellung von 10-deacetyl-n-debenzoyl-paclitaxel
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
US8691780B2 (en) * 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
KR20080100264A (ko) * 2006-03-21 2008-11-14 닥터 레디스 레보러터리즈 리미티드 도세탁셀의 다형체와 그 제조방법
MX2008011978A (es) 2006-03-22 2009-04-22 Medigene Ag Tratamiento del cancer de seno negativo al triple receptor.
ITMI20062479A1 (it) * 2006-12-21 2008-06-22 Indena Spa Processo per la preparazione di secotassani
EP2151363B1 (de) * 2007-05-30 2011-08-17 Mitsubishi Electric Corporation Bremssteuerungsgerät für ein elektrisches fahrzeug
EP2296645B1 (de) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Antitumorale kombinationstherapie
KR101003822B1 (ko) 2008-06-20 2010-12-27 주식회사 셀트리온화학연구소 도세탁셀의 제조방법 및 도세탁셀의 제조를 위한 신규한중간체
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
CN101735179B (zh) * 2008-11-19 2012-09-12 上海百灵医药科技有限公司 一种多烯紫杉醇的制备方法,其中间体及制备方法
EP2358693A4 (de) * 2008-11-20 2012-04-18 Reddys Lab Ltd Dr Herstellung von docetaxel
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
EP3539563A1 (de) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Für cd22 spezifischer antikörper und verfahren zur verwendung davon
CN104884056A (zh) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
JP6450690B2 (ja) 2013-02-15 2019-01-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア キメラ抗原受容体及びその使用方法
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法
EP3074010A4 (de) 2013-11-27 2017-10-25 Redwood Bioscience, Inc. Hydrazinylpyrrolverbindungen und verfahren zur herstellung eines konjugats
JP6615769B2 (ja) 2014-02-19 2019-12-04 アルデア ファーマシューティカルズ インコーポレイテッド ミトコンドリアアルデヒドデヒドロゲナーゼ2(aldh2)に結合する多環式アミド
PE20211798A1 (es) 2014-03-21 2021-09-13 Abbvie Inc Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
US10654875B2 (en) 2015-11-12 2020-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
EP3231421A1 (de) 2016-04-11 2017-10-18 Greenaltech, S.L. Verwendungen eines carotenoids bei der behandlung oder prävention von durch stress verursachten störungen
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
SI3463308T1 (sl) 2016-06-01 2022-04-29 Servier IP UK Limited Formulacije polialkilenoksidne asparaginaze in postopki za pripravo in uporabo le-teh
CN116284404A (zh) 2016-06-08 2023-06-23 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
MX2018015272A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
BR112018075653A2 (pt) 2016-06-08 2019-08-27 Abbvie Inc anticorpos anti-b7-h3 e conjugados anticorpo fármaco
JP2019521973A (ja) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗bh7−h3抗体及び抗体薬物コンジュゲート
CN109562169A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
TW201825087A (zh) 2017-01-05 2018-07-16 杏國新藥股份有限公司 胰臟癌治療
EP3571229A1 (de) 2017-01-18 2019-11-27 F1 Oncology, Inc. Chimäre antigenrezeptoren gegen axl oder ror2 und verfahren zur verwendung davon
EP3388082A1 (de) 2017-04-13 2018-10-17 Galera Labs, LLC Kombinationskrebsimmuntherapie mit makrocyclischem pentaaza-ringkomplex
JP2021512110A (ja) 2018-01-31 2021-05-13 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
WO2019200181A1 (en) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
EP3823674A4 (de) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. Konjugate zur abgabe eines krebsmittels an nervenzellen, verwendungsverfahren und verfahren zu deren herstellung
JP2022527860A (ja) 2019-04-02 2022-06-06 ケンジョッケティ バイオテクノロジー,インク. 排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
WO2021155028A1 (en) 2020-01-29 2021-08-05 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
WO2021247423A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2021247426A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
EP4208483A1 (de) 2020-09-02 2023-07-12 Kenjockety Biotechnology, Inc. Anti-abcc1-antikörper und verwendungen davon
EP4244257A1 (de) 2020-11-13 2023-09-20 Kenjockety Biotechnology, Inc. Anti-mrp4 (codiert durch abcc4-gen) antikörper und verwendungen davon
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CA3238353A1 (en) 2021-12-13 2023-06-22 William Robert ARATHOON Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175315A (en) * 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5319112A (en) * 1992-08-18 1994-06-07 Virgnia Tech Intellectual Properties, Inc. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol

Also Published As

Publication number Publication date
AU5115093A (en) 1994-04-26
JPH08501788A (ja) 1996-02-27
CZ283261B6 (cs) 1998-02-18
FI951595A (fi) 1995-04-04
US5677462A (en) 1997-10-14
ATE146174T1 (de) 1996-12-15
TW419472B (en) 2001-01-21
EP0663906A1 (de) 1995-07-26
EP0663906B1 (de) 1996-12-11
FR2696458A1 (fr) 1994-04-08
GR3021997T3 (en) 1997-03-31
WO1994007877A1 (fr) 1994-04-14
DE69306591T2 (de) 1997-04-17
KR950703546A (ko) 1995-09-20
HUT72679A (en) 1996-05-28
US5616739A (en) 1997-04-01
RU95113717A (ru) 1996-12-27
PL182284B1 (pl) 2001-12-31
NO951201L (no) 1995-03-29
JP3014760B2 (ja) 2000-02-28
FI109793B (fi) 2002-10-15
FR2696458B1 (fr) 1994-11-10
FI951595A0 (fi) 1995-04-04
ES2095081T3 (es) 1997-02-01
DK0663906T3 (da) 1996-12-30
ZA937318B (en) 1994-04-25
SK43695A3 (en) 1995-08-09
RU2116303C1 (ru) 1998-07-27
AU689080B2 (en) 1998-03-26
CA2146250A1 (fr) 1994-04-14
MX9305766A (es) 1995-01-31
NZ256445A (en) 1997-01-29
KR100311198B1 (ko) 2002-04-24
DE69306591D1 (de) 1997-01-23
SK280627B6 (sk) 2000-05-16
CZ84195A3 (en) 1995-09-13
HU226412B1 (en) 2008-11-28
CA2146250C (fr) 2003-03-11
PL308241A1 (en) 1995-07-24
NO951201D0 (no) 1995-03-29
HU9500971D0 (en) 1995-06-28
US5869680A (en) 1999-02-09

Similar Documents

Publication Publication Date Title
NO309089B1 (no) FremgangsmÕte for fremstilling av taxanderivater
NO311255B1 (no) Fremgangsmåte for fremstilling av taxanderivater samt mellomprodukter til bruk ved fremstillingen
FI109791B (fi) Menetelmä taksaanijohdannaisten valmistamiseksi, menetelmän lähtöaine ja välituote
JP3064419B2 (ja) バッカチン▲iii▼及び10−デアセチルバッカチン▲iii▼のエステル化のための新規な方法
FI109798B (fi) Menetelmä taksaanivälituotteiden valmistamiseksi, lähtöaineet taksaanivälituotteiden valmistamiseksi ja taksaanivälituotteet
JP2007022932A (ja) アミノ酸−n−カルボキシ無水物の製造方法
SK281297B6 (sk) Spôsob prípravy beta-fenylizoserínu, jeho analógov a medziprodukt
AU2003219094B2 (en) A semi-synthetic process for the preparation of N debenzoylpaclitaxel
FI119289B (fi) Menetelmä (4S, 5R)-1,3-oksatsolidin-5-karboksyylihapon valmistamiseksi ja menetelmä taksaanijohdannaisten valmistamiseksi näin saatua karboksyylihappoa käyttäen
Monir et al. A mild approach to synthesise enantiopure glycine-derived 5-phenylthiomorpholinone
Mohalid et al. Chemical exploration of 4-hydroxybenzylated 3-substituted tetramic acid
SK92994A3 (en) Acids anhydrides and method of their preparation and use
WO2015036522A1 (en) Process for the preparation and isolation of (s)-3-amino-n-cyclopropyl-2,2-dialkoxyhexanamide and (s)-tert-butyl(1-(cyclopropylamino)-2,2-dialkoxy-1-oxohexan-3-yl)carbamate and use thereof for the preparation of telaprevir

Legal Events

Date Code Title Description
MK1K Patent expired